Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down15.440 -0.020 (-0.129%)

28/05/2020 18:01

CSPC Pharma (01093) product gets clinical trial approval

[ET Net News Agency, 28 May 2020] CSPC Pharmaceutical Group Limited (01093) said
"SYHA1805" developed by the group has obtained approval granted by the National Medical
Products Administration of the People's Republic of China to conduct clinical trials in
The product is a new type of small-molecule agonist and currently there is no product of
the same type available in the global market. The clinical indication for this approval is
the treatment of nonalcoholic steatohepatitis (NASH). The pre-clinical studies have shown
that the product has a high selectivity of efficacy targets, can significantly ameliorate
liver fibrosis and has excellent in vivo and in vitro activities as well as good safety,
providing a promising prospect of demonstrating good efficacy in the clinical trials. (RC)

Remark: Real time quote last updated: 14/08/2020 17:58
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.